

---

---

# JEFFREY S. TURNER

2080 Century Park East, Suite 1005  
Los Angeles, CA 90067

---

---

## EXPERIENCE

**Medical Oncologist**, July 2009 - current

*Compassionate Oncology Medical Group*, Los Angeles, CA

- Prostate cancer specialist

**Hospitalist**, January 2007 – June 2007

*Presbyterian Intercommunity Hospital*, Whittier, CA

- ER admissions, preoperative/postoperative consultations
- Assisting other hospitalists with daytime rounding and admissions as necessary

**Hospitalist**, July 2006 – December 2006

*South Coast Medical Center*, Laguna Beach, CA

- ER admissions, preoperative/postoperative consultations
- Medical clearance consultations for psychiatric and chemical dependency recovery program units
- Assisting other hospitalists with daytime rounding and admissions as necessary

## EDUCATION/TRAINING

**Fellowship – Medical Oncology**, 2007-2009

*Medical University of South Carolina*, Charleston, SC

July 1, 2007 – June 30, 2009

**Residency – Internal Medicine**, 2003-2006

*University of British Columbia*, Vancouver, BC, CANADA

July 1, 2003 – June 30, 2006

**Medical Degree**, 1999-2003

*Memorial University of Newfoundland*, St. John's, NL, CANADA

- 1 of 5 American students (LCME accredited)

**Bachelor of the Arts – Biological Sciences**, cum laude, 1993-1996

*University of Southern California*

- 1<sup>st</sup> student to graduate from USC's 3-year accelerated science degree program
- Dean's Scholar / Golden State Scholar / 'SCions Scholar / Golden Key Nat'l Honor Society

## LICENSURE / CERTIFICATION

California Medical License – March 8, 2006

Drug Enforcement Administration License – June 20, 2006

American Board of Internal Medicine Certified - August 18, 2006

American Board of Medical Oncology Certified - November 12, 2009

South Carolina Medical License – 2007

Dept. of Health and Environmental Control License (SC) - 2007

## PROFESSIONAL MEMBERSHIPS

American Society of Clinical Oncology (Since 2004)  
American College of Physicians – Internal Medicine (Since 2003)  
American Society of Hematology (Since 2007)

## OTHER EMPLOYMENT / RESEARCH

**UCLA:** June 1, 2000 – August 1, 2000

***Staff Research Associate***

Department of Host-Defense & Immunology

Designed and developed TNF- $\alpha$  ELISA assay for the purpose of studying antimicrobial peptide/LPS interactions in the setting of red blood cell membrane stability.

**Consolidated Laboratory Services:** October 1, 1998 – July 1, 1999

***Research Associate***

HIV clinical laboratory – private sector

Performing gene-sequencing & genotyping, nucleic-acid sequence-based amplification, PCR assays.  
Monitoring clinical trials of new protease and RT inhibitors.

**UCLA:** August 1, 1996 – October 1, 1998

***Staff Research Associate***

Department of Host-Defense & Immunology:

Performing collaborative work on the study of antimicrobial peptides – radial diffusion assays, LPS binding assays, as well as hemolytic/cytotoxic analyses.

## PUBLICATIONS

September 1998

Activities of LL-37, a cathelin-associated antimicrobial peptide of human neutrophils.

**Turner J**, Cho Y, Dinh NN, Waring AJ, Lehrer RI.

Antimicrobial Agents & Chemotherapy

42(9), 2206-2214

June 1998

Activity of Protegrins against Yeast-Phase *Candida albicans*.

Cho Y, **Turner J**, Dinh NN, Lehrer RI.

Infection and Immunity

66(6), 2486-2493

March 2000

Evaluation of the Inactivation of Infectious Herpes Simplex Virus by Host-Defense Peptides.

Yasin B, Pang M, **Turner JS**, Cho Y, Dinh NN, Waring AJ, Lehrer RI.

European Journal of Clinical Microbiology and Infectious Diseases

19(3), 187-194

September 1999

Genotyping of HIV-1 Drug Resistance: Comparison between in-house procedure and Visible Genetics TruGene HIV-1 Assay.

Lee SY, Espin F, **Turner J**, Griswold M, Kahn D.

Abstracts of 39<sup>th</sup> Conference on Antimicrobial Agents & Chemotherapy  
p. 462

April 2007

Pain management, supportive and palliative care in patients with renal cell carcinoma.

**Jeffrey S. Turner**, Eric M. Cheung, Jaya George, David I. Quinn.

British Journal of Urology International

Volume 99, Issue 5b, 1305-1312

December 2008

Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate cancer.

AntiCancer Drugs.

**Turner J.**, Chaudhary UB.

May 2009 ASCO General Meeting (Abstract #e16053)

Bortezomib therapy for PSA relapse after definitive local therapy for prostate cancer.

J Clin Oncol 27, 2009 (suppl; abstr e16053)

**Turner, J**, Kraft, A.

#### **PENDING PUBLICATIONS (ACCEPTED)**

Encyclopedia of Cancer – Chapter on Renal Cell Carcinoma

Finasteride (focus on Prostate Cancer Prevention Trial) – Expert Opinion

Pazopanib – Expert Opinion in respect to Renal Cell Carcinoma

#### **POSTERS/OTHER**

“Comparison of combined chemotherapy to conventional radiotherapy in the treatment of Stage 2A/B testicular seminoma.”

- Awarded BEST POSTER PRESENTATION by a 2<sup>nd</sup> year resident – UBC 2005 Annual Resident Research Day

Completed 1 month elective in GU medical oncology at MD Anderson Cancer Center (April 2005) under the supervision of GU medical oncology chair Dr. Christopher Logothetis

#### **CRITIQUED REVIEWS**

1. Clinical Genitourinary Cancer: Meningeal Carcinomatosis: An extremely rare metastasis of urinary bladder carcinoma” [Paper #CPC07045CS]
2. Current Cancer Drug Targets: Vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) pathways as targets in the treatment of advanced renal cell carcinoma. D. Heng, R. Bukowski – Experimental Therapeutics, Cleveland Clinic Taussig Cancer Institute. Current Cancer Drug Targets.